Insuman Rapid 100 IU/ml solution for injection in a cartridge
Authorisation EU/1/97/030/055 · Sanofi-Aventis Deutschland GmbH
- Licence holder
- Sanofi-Aventis Deutschland GmbH (all products →)
- Active substance
- Insulin human
- Dosage form
- Solution for injection in cartridge
- Routes of administration
- Intramuscular use, Subcutaneous use
- ATC codes
- A10AB, A10AB01
- First authorised
- 18/02/1999
- Prescription status
- Product subject to prescription which may be renewed (B)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Insulin human: supply and approvals
51 authorised products on the HPRA list contain Insulin human. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.
- EU shortage (EMA)
-
Insuman Rapid, Basal and Comb 25 (insulin human): Shortage ongoing, first published 24 Jan 2023
Insuman Basal and Comb 25: Medicine discontinued, first published 1 Dec 2015
Insuman Rapid, Basal and Comb: Shortage resolved, first published 31 Mar 2015 - US shortage (FDA)
- No entry in the FDA drug shortage list (checked 20 Nov 2026)
- Germany (BfArM)
- No entry in the BfArM supply notices (checked 20 Nov 2026)
Registers: EU shortages · US shortages · German shortages · EMA approvals
About this licence
Centralised EU authorisation. This product holds an EU-wide marketing authorisation granted by the European Commission after assessment by the European Medicines Agency, valid in every EU country. Its EU product number is 030. It has been authorised for 27 years (since 18 February 1999). The HPRA list does not say whether it is on sale.
Other medicines with Insulin human in Ireland
50 other products on the HPRA list contain Insulin human, from 2 licence holders; 0 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.
| Medicine | Licence holder | Licence | Status |
|---|---|---|---|
| Actraphane | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Actraphane 30 40 IU/ml Suspension for injection | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Actraphane 30 40 IU/ml Suspension for injection | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Actrapid | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Actrapid | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Insulatard | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Insulatard 100 international units/ml suspension for injection in vial | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Insulatard FlexPen | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Insulatard InnoLet | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Insulatard Penfill | Novo Nordisk A/S | Centralised EU authorisation | Not stated |
| Insuman Basal 100 IU/ml suspension for injection in a cartridge | Sanofi-Aventis Deutschland GmbH | Centralised EU authorisation | Not stated |
| Insuman Basal 100 IU/ml suspension for injection in a cartridge | Sanofi-Aventis Deutschland GmbH | Centralised EU authorisation | Not stated |
Other substances in ATC group A10AB
The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 4 other active substances share the group A10AB with this product:
Insulin lispro (12) · Insulin aspart (7) · Insulin glulisine (2) · Human insulin (recombinant dna origin) (1)
Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.
The licence holder
Sanofi-Aventis Deutschland GmbH holds 56 products on the HPRA list, with 5 different active substances; 0 of the products are marked as marketed.
This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.
How this page is built
The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.
- HPRA Authorised Medicines List (open data) ↗ Licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status for this product
This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 21 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.